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Objective: We sought to assess the effects of insulin-like growth factor 1 on the
balance between systemic oxygen consumption and oxygen delivery after cardio-
pulmonary bypass in piglets.
Methods: Twelve piglets weighing 4.5 to 8.3 kg undergoing hypothermic (28°C)
cardiopulmonary bypass for 70 to 120 minutes with 40 minutes of aortic cross-
clamping were studied before and during the first 6 hours after cardiopulmonary
bypass. Oxygen consumption was continuously measured by an indirect calorime-
ter, Deltatrac II MBM-200 Metabolic Monitor (Datex Division Instrumentarium,
Helsinki, Finland). Oxygen delivery and cardiac output were calculated from
oxygen consumption and the arterial and mixed venous oxygen contents sampled
before and every 30 minutes after cardiopulmonary bypass. Oxygen extraction ratio
was derived by the ratio of oxygen consumption to oxygen delivery. Arterial blood
lactate was measured before and every 30 minutes after cardiopulmonary bypass.
Six animals were randomly assigned to receive an intravenous infusion of insulin-
like growth factor 1 at 1.2 mg/h from 1 to 6 hours after cardiopulmonary bypass; the
remaining 6 served as a control group.
Results: Relative to the control group, intravenous infusion of insulin-like growth
factor 1 significantly reduced oxygen consumption (P  .02) and increased cardiac
output (P  .016) and oxygen delivery (P  .049) during the first 6 hours after
surgery with hypothermic cardiopulmonary bypass. As a result, oxygen extraction
was significantly decreased (P  .012).
Conclusions: Intravenous infusion of insulin-like growth factor 1 improved oxygen
transport by reducing oxygen consumption as well as increasing cardiac output and
oxygen delivery during the first 6 hours after cardiopulmonary bypass in piglets.
This may have important clinical implications for the care of critically ill children
after surgery with cardiopulmonary bypass.
The balance between systemic oxygen delivery (DO2) and oxygenconsumption (V˙ O2) is impaired after surgery with cardiopulmonarybypass (CPB). DO2 is typically decreased as a result of diminishedcardiac output (CO), whereas V˙ O2 may be increased, reflecting ahypercatabolic response. The hypercatabolism has been shown to bein part a consequence of a disordered growth hormone and insulin-
like growth factor (IGF-1) axis, with depressed IGF-1 levels having been reported
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in patients after CPB1 and other critical illness.2-5 Recently,
there has been considerable interest in the role of IGF-1 in
illness-related hypercatabolism. First, circulating IGF-1 has
been confirmed to have a tonic role in sustaining a general
anabolic state and therefore potentially could reduce V˙ O2 by
countering the catabolic response.6-9 Second, IGF-1 has
been shown to have positive inotropic properties by sensi-
tizing the myofilaments to calcium ion,10 which may in-
crease CO and DO2.
Nonetheless, there have been no data reported on the
effect of IGF-1 on the overall balance of oxygen transport.
The aim of our study was therefore to assess the effects of
IGF-1 on the balance between V˙ O2 and DO2 after CPB in
young animals.
Methods
Anesthesia
The institutional animal research committee approved the use of
Danish Landrace pigs. Twelve animals, aged 2 to 3 weeks and
weighing 4.5 to 8.3 kg (mean 6.7 kg), were medicated intramus-
cularly with ketamine (100 mg) and midazolam (5 mg). All were
intubated with cuffed endotracheal tubes and mechanically venti-
lated with volume-cycled, intermittent, positive-pressure ventila-
tion (Servo 900C; Siemens Medical Systems, Solna, Sweden).
Anesthesia was subsequently maintained with a continuous intra-
venous infusion of fentanyl (300 g/h), midazolam (20 mg/h), and
pancuronium bromide (2 mg/h). The right carotid artery and in-
ternal jugular vein were cannulated for arterial pressure monitor-
ing, blood sampling, and infusions. Bladder catheterization was
performed.
CPB
After median sternotomy and heparinization (unfractionated hep-
arin at 300 IU/kg), a pulmonary arterial line was inserted. Animals
underwent CPB with a standard clinical neonatal circuit with
cannulation of the ascending aorta and right atrium (Sto¨ckert 2.6F
and right-angled 20F cannula; Medtronic DLP, Grand Rapids,
Mich), a hollow-fiber membrane oxygenator (Dideco SpA, Miran-
dola, Italy), and a twin roller pump (JOSTRA Medizintechnik AG,
Hirrlingen, Germany). The bypass machine was primed with 350
mL whole blood. Animals underwent 70 to 120 minutes (mean 87
minutes) of hypothermic CPB (28°C) with 40 minutes of aortic
crossclamping and cardioplegic arrest (4°C, St Thomas solution,
30 mL/kg). CPB was continued during rewarming, until rectal
temperature was restored to 38°C and hemodynamic stability was
achieved. Throughout CPB, the nonpulsatile flow was maintained
between 75 and 100 mL/kg so that the mean perfusion pressure was
adjusted between 40 and 50 mm Hg, with additional use of nitroglyc-
erin for vasodilation as required. Protamine sulfate (1 mL/1000 IU
heparin) was given immediately after CPB. Positive-pressure venti-
lation was recommenced after discontinuation of CPB.
Post-CPB Care
Routine intensive care vital signs (blood pressure, heart rate,
central venous pressure, pulmonary arterial pressure, rectal tem-
perature, and urinary output) and ventilator tidal volumes and
pressures were continuously monitored. An electric warming blan-
ket was used; otherwise, no adjustments were made to temperature
during the experiments. Hemoglobin was maintained at 5 to 7 g/dL
with donor blood, and hematocrit was kept at around 20%.
Throughout the experiments, a fluid containing 20-mmol/L potas-
sium chloride, 20.5-mmol/L sodium chloride, and 2.31-mmol/L
glucose was infused through a central venous line. Dobutamine
and nitroglycerin were used according to hemodynamic condi-
tions. The aim was to maintain a systolic arterial blood pressure of
more than 70 to 80 mm Hg, a urinary output of more than 1 mL/(kg
· h), adequate peripheral perfusion, and a nonacidotic state. Addi-
tional 20% glucose was infused in the IGF-1 group, with the rate
adjusted to maintain the glucose levels above 4 mmol/L.
Methods of Measurement
V˙ O2. V˙ O2 was measured continuously by respiratory gas anal-
ysis with an open-circuit indirect calorimeter, Deltatrac II MBM-
200 Metabolic Monitor (Datex Division Instrumentarium, Hel-
sinki, Finland).11,12 This calorimeter contains a fast differential
paramagnetic oxygen sensor to measure a difference between
inspired and expired concentrations and the absolute concentration
in the inspired gas, an infrared carbon dioxide sensor, and a gas
dilution system to measure flow. The apparatus has been described
in detail previously elsewhere.13,14 Briefly, all expired gas from
the ventilator enters the 4-L mixing chamber, from which gas is
sampled and analyzed to determine mixed expired oxygen (FEO2)
and carbon dioxide (FECO2) concentrations. The expired gas leav-
ing the mixing chamber is then mixed with room air so that the
total flow (Q˙ ) is constant. Diluted carbon dioxide fraction (F*CO2)
is measured, and the carbon dioxide production volume (V˙ CO2) is
calculated as follows:
V˙ CO2  Q˙  F*CO2 (1)
The respiratory quotient (RQ), or the ratio of (V˙ CO2 and V˙ O2, is
calculated by means of the Haldane transformation as follows:
RQ 1 FIO2
FIO2 FEO2/FECO2 FIO2
(2)
where FIO2 indicates the inspired oxygen concentration sampled at
the inspiratory limb of the ventilator circuit.
The V˙ O2 is subsequently calculated from the RQ as follows:
V˙ O2 V˙ CO2/RQ (3)
Gas volumes are corrected to standard conditions of dry gas,
temperature and pressure. In this study, the artifact suppression
mode was used. FIO2 was less than 0.4 in all subjects during the
study. Changes in minute volume and FIO2 were avoided 15
minutes before measurement was taken. Calibration was per-
formed before each experiment. The Deltatrac device measures
V˙ O2 every 1 minute, and the mean of at least 5 values was taken.
DO2, CO, oxygen extraction ratio, and blood lactate. Arterial
and mixed venous blood samples were taken from the peripheral
arterial and pulmonary arterial catheters. Blood samples were
analyzed for oxygen, carbon dioxide, lactate, and glucose levels
with a blood analyzer (Radiometer ABL System 615; Radiometer
Medical A/S, Brønshøj, Denmark). CO was then calculated with
the direct Fick method according to the following equation:
Li et al Surgery for Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 5 1437
CH
D
CO V˙ O2/CaO2 CvO2 (4)
where CaO2 and CvO2 are arterial and mixed venous oxygen
contents, respectively. DO2 was then calculated by the following
equation:
DO2  CO  CaO2 (5)
and oxygen extraction rate (ERO2) was calculated by the following
equation:
ERO2  VO2/DO2 (6)
Study Protocol
Hemodynamic values, V˙ O2, and rectal temperature were obtained,
and blood samples were taken at the following times: after induc-
tion of anesthesia (baseline), 30 minutes after CPB, and then every
30 minutes until 6 hours after CPB. Intravenous infusion of IGF-1
at 1.2 mg/h was commenced 1 hour after the termination of CPB,
when the subject was rewarmed and stabilized, and continued to 6
hours after the termination of CPB.
Statistical Analysis
Data are expressed as mean  SE. Comparisons of the values
between baseline and after CPB within the group were carried out
with the unpaired 2-tailed t test. Comparisons of the changes of the
values over the study period between the control and IGF-1 groups
were performed with mixed linear regression for repeated serial
measurements. The changes in each variable during the study
period were analyzed with 1-way repeated measures of analysis of
variance. Correlation between two data sets was assessed with the
correlation coefficient.
Results
Figure 1 demonstrates V˙ O2, CO, DO2, ERO2, central tem-
perature, and arterial blood lactate levels during the study
period in the IGF-1 and control groups.
Baseline Measures
Piglets weighed 6.9  0.5 kg in the IGF-1 group (n  6)
and 6.5 0.6 kg in the control group (n 6, P .05). CPB
times were 93  8 minutes in the IGF-1 group and 80  4
minutes in the control group (P  .05). The baseline values
of V˙ O2 (7.55  0.60 vs 7.77  0.55 mL/[min · kg]), ERO2
(0.46  0.08 vs 0.48  0.03), lactate (1.88  0.68 vs 2.20
 0.34 mmol/L), and central temperature (38.2°C  0.4°C
vs 38.5°C  0.4°C) were lower in the IGF-1 group than in
the control group, whereas CO (0.29  0.05 vs 0.23  0.02
L/[min · kg]) and DO2 (19.74  3.93 vs 16.36  1.43
mL/[min · kg]) were higher; however, none of these differ-
ences were considered to be of statistical significance (P 
.05 for all).
Changes After CPB
The values of central temperature, V˙ O2, DO2, CO, and ERO2
at 30 minutes after CPB were lower than baseline for both
the IGF-1 and control groups, except for CO in the IGF-1
group, which was slightly higher, but without statistical
significance in all the values (P  .05). Blood lactate levels
were significantly higher than baseline values after CPB for
both groups (P .001 for both). No correlations were found
between the duration of CPB and V˙ O2 immediately after
CPB, at 1 hour after CPB, and at 6 hours after CPB. (r 0.2
to 0.4, P  .05 for all).
Comparison of Changes Between IGF-1 and Control
Groups After CPB
In the IGF-1 group, V˙ O2 initially increased after CPB to 8.1
mL/(min · kg) at 2 hours (1 hour after the infusion of
IGF-1). The increase was insignificant relative to the first
measurements at 30 minutes after CPB (P  .05). Between
2 and 6 hours, there was a significant fall in V˙ O2 in the
IGF-1 group (P  .002); V˙ O2 in the control group also
decreased during this period. The decrease in V˙ O2 in the
IGF-1 group was significantly greater than that in the con-
trol group (P  .02). During the same period, central
temperature remained relatively stable in the IGF-1 group,
whereas it increased in the control group (P  .008). Both
CO and DO2 were higher in the IGF-1 group throughout the
study period. During the last 4 hours, CO and DO2 showed
increases in the IGF-1 group but remained at similar levels
in the control group (P  .016 and P  .049, respectively).
As a result, ERO2 was significantly decreased in the IGF-1
group relative to the control group (P  .012). Lactate
decreased significantly in both groups (P  .001), being
significantly greater in the control group (P  .015). None-
theless, it had returned to the normal range (2.5 mmol/L)
by the end of the study period in both groups. The average
doses of dobutamine and nitroglycerin and the fluid infusion
were similar in both groups. In the IGF-1 group, an addi-
tional 20% glucose infusion was needed so that the blood
glucose was maintained at levels similar to those in the
control group (4 mmol/L, P  .05).
Discussion
This is the first study to assess the effects of IGF-1 on the
balance between systemic V˙ O2 and DO2 during the early
hours after CPB. Our data shows that intravenous infusion
of IGF-1 significantly reduced V˙ O2 while maintaining the
central body temperature and was associated with increased
CO and DO2 during the first 6 hours after CPB. Therefore it
improved the balance between V˙ O2 and DO2, as indicated by
a significant decrease in ERO2.
Effect of IGF-1 on V˙ O2
It is well documented that V˙ O2 increases during the early
hours after CPB,15-19 and that the increase is related to
central body temperature17,19 and to the systemic inflam-
matory response.18 The initial postoperative V˙ O2 in our
animals was lower than baseline in all the animals, as was
central temperature, reflecting incomplete rewarming after
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CPB. The subsequent increase in V˙ O2 during the following
2 or 3 hours in both groups is consistent with our own and
other previous studies.15-19 However, there was a significant
decrease in V˙ O2 within 1 hour of starting the intravenous
infusion of IGF-1.
Circulating IGF-1 levels are uniformly low in hypercata-
bolic states in various diseases, including after surgery with
CPB.1-5 This may be because the acquired growth hormone
resistance fails to stimulate the synthesis and release of
IGF-1, leading to the failure of the liver to produce IGF-1 in
these circumstances.20,21 Administration of IGF-1 has been
reported to attenuate protein catabolism and promote anab-
olism in postoperative6 and other critically ill subjects.7,9
Strock and colleagues7 reported that the decrease in IGF-1
Figure 1. Values of central temperature (A, in °C), V˙O2 (B, in mL/[min · kg]), CO (C, in L/[min · kg]), DO2 (D, in mL/[min
· kg]), ERO2 (E), and arterial blood lactate (F, in mmol/L) during first 6 hours after CPB in piglets receiving
intravenous infusion of IGF-1 started (dashed line) 1 hour after CPB (filled circles, n 6) and in control group (open
circles, n  6). Data points represent mean; error bars represent SE.
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levels coincided with the period of most pronounced hyper-
metabolic response in a rat model of burn injury, and that
treatment with IGF-1 reduced metabolic rate and V˙ O2 and
increased body weight significantly during a period of 14
days. Our study shows similar effects of IGF-1 in subjects
after CPB. Interestingly, this response was accompanied by
a significantly lower temperature (P  .008) than in the
control group, perhaps reflecting attenuated catabolism.
The mechanisms by which IGF-1 brings about this de-
crease in postoperative V˙ O2 and metabolic rate in the post-
operative animals cannot be explained by a direct effect on
temperature control, because IGF-1 is not antipyretic.
Rather, it is best explained by the substance’s anabolic
effects. While being stimulated by and mediating the
growth stimulatory effect of growth hormone, IGF-1 exerts
insulin-like metabolic effects with the cross-reaction with
the insulin receptor on the energy substrates. It has been
reported that administration of IGF-1 may increase protein
synthesis6 as well as reduce protein breakdown,22 which
may be associated with a reduction in V˙ O2. In addition, the
insulin-like effect of IGF-1 that promotes glucose as energy
substrate by stimulating peripheral uptake and glucose ox-
idation instead of fat by suppressing lipolysis23 may further
contribute to the reduction of V˙ O2, because glucose oxida-
tion is less oxygen demanding than is fat oxidation.22,24
Most studies assessing the anabolic effect of IGF-1 have
been performed through a period of several days6,7; the
significantly reduced V˙ O2 in our more acute study may
indicate the anabolic effect of IGF-1 during the early hours
after CPB. Although the mechanisms remain a matter of
speculation, IGF-1 may provide beneficial effects in terms
of both oxygen transport and anabolism to accelerate post-
operative recovery after CPB.
Effect of IGF-1 on DO2
DO2 is decreased after CPB primarily because of depressed
cardiac function.25,26 The mechanism of the fall in cardiac
function remains undefined but may be related to ischemia-
reperfusion injury, direct trauma, cytokines, and other myo-
cardial depressants.27,28 Administration of IGF-1 has been
reported to confer cytoprotection against ischemia and
reperfusion injury and thus to accelerate recovery of post-
ischemic cardiac function.25 In addition, IGF-1 may have
distinct positive inotropic properties, leading to an increase
in CO.10,25 These factors may contribute to the significant
increases in CO and DO2 in our study in the IGF-1 group
relative to the control group. Unlike with inotropic drugs,
however, the increase in cardiac contractility by IGF-1 may
not come at the expense of increasing myocardial V˙ O2,
because it significantly increases myofilament free calcium
sensitivity rather than increasing myocyte free calcium con-
centration.10 This unique property of IGF-1 may offer a
significant therapeutic benefit in treating a myocardium with
limited DO2, such as is often encountered in patients after
surgery with CPB. Overall, intravenous infusion of IGF-1
improved the balance of oxygen transport, as indicated by a
significant decrease in ERO2 relative to the control group.
Assessment of blood lactate is increasingly used as a sur-
rogate for tissue oxygen use, and although the decrease in
blood lactate was significantly greater in the control group,
it returned to the normal range in both groups.
Effect of IGF-1 on Blood Glucose Levels
The insulinlike effect of IGF-1 to stimulate glucose uptake
and oxidation may be potentially beneficial in postoperative
patients. Van den Berghe and associates29 recently reported
that normalization of blood glucose levels with intensive
insulin therapy reduced mortality and morbidity among
critically ill patients in the surgical intensive care unit,
regardless of whether they had a history of diabetes, al-
though the mechanisms remain a matter of speculation.
IGF-1 has been shown to be 6% as potent a hypoglycemic
agent as insulin.30 Hypoglycemia remains a potential com-
plication, although it has been reported that with continuous
administration of IGF-1 the acute hypoglycemia may be less
pronounced because of the transferring of free IGF-1 to its
binding proteins.31 The blood glucose levels tended to de-
crease to low levels because of the relatively high dose of
1.2 mg/h in the piglets in our study. Thus careful attention
to the prevention of hypoglycemia is essential when using
IGF-1.
Conclusion
Intravenous infusion of IGF-1 improved oxygen transport
by reducing V˙ O2 as well as increasing CO and DO2 during
the first 6 hours after CPB in young piglets. This may have
important clinical implications for the care of critically ill
children after CPB surgery.
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